FibroBiologics files patent application for fibroblast-based therapeutics
FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods ...
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc.
Windtree Therapeutics announces notice of allowance from USPTO for istaroxime
Windtree Therapeutics (WINT) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. application ...
AutoGuide1h
The World Is Ready For A Mustang Sedan
Ford recently filed the name "Mach 4" with the United States Patent and Trademark Office (USPTO) on February 25. The ...
JD Supra18h
USPTO Rescinds 2022 Guidance on Discretionary Denials
On February 28, 2025, the United States Patent and Trademark Office announced that it has rescinded the June 21, 2022, ...
medtechdive23h
Osteoboost Health, Inc. Awarded 6th U.S. Patent for Osteoboost, a Wearable Device for Bone Density Improvement
This is Osteoboost’s 6th patent in the US. It is expected to launch in Q2 2025.
Fibrobiologics, Inc.: FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc.
Common malaria drug repurposed to fight cancer
Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have ...
Hosted on MSN13h
Hyundai's New Performance Models Will Take Aim At BMW's Best-Selling M Cars
Just like German automakers, Hyundai wants to sell the impression of performance for those who can't afford the real thing.
Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...